Xie Hao, Jiang Lin, Peng Junya, Hu Haoyang, Han Meifen, Zhao Bin
Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Front Pharmacol. 2025 Apr 16;16:1564127. doi: 10.3389/fphar.2025.1564127. eCollection 2025.
Drug-induced pancreatitis is a rare disease but frequently reported, owing to the vast number of medications.
To summarize potential drugs causing pancreatitis and to speculate on underlying mechanisms.
We extracted more than 60,000 reports of pancreatitis submitted to the U.S. Food and Drug Administration Adverse Event Reporting System (January 2004 to March 2023). Data on patient age, sex, weight, time to onset, and outcome (death et al.) were collected. Disproportionality analysis was used in data mining to identify associations between drugs and pancreatitis events. Seven databases, commonly used for network pharmacology analysis, were searched to identify potential targets.
Of 867 drugs with 3 or more reports, 101 drugs met all criteria using disproportionality analysis and indicated a potential risk of pancreatitis. The risk of 40 drugs had not been previously noted in "UpToDate" database. Patients taking the drugs had a similar sex distribution, were mostly 45-64 years old, and were heavier (median, 88 kg; P < 0.0001). The median time to onset was 199 days (interquartile range, 27-731.5). Ponatinib (16.48%), tigecycline (14.12%) and valproic acid (13.41%) had higher fatality rates. Potential targets related to pancreatitis were identified in 50 of the 101 drugs.
Clinicians providing the 101 drugs for treatment should stay vigilant to detect pancreatitis early.
药物性胰腺炎是一种罕见疾病，但由于药物种类繁多，其报告病例数却屡见不鲜。
总结可能导致胰腺炎的药物，并推测其潜在机制。
我们从提交给美国食品药品监督管理局不良事件报告系统（2004年1月至2023年3月）的60,000多份胰腺炎报告中提取数据。收集患者的年龄、性别、体重、发病时间和结局（死亡等）数据。在数据挖掘中使用不成比例分析来确定药物与胰腺炎事件之间的关联。检索了常用于网络药理学分析的七个数据库，以确定潜在靶点。
在867种有3份或更多报告的药物中，101种药物通过不成比例分析符合所有标准，表明存在胰腺炎潜在风险。“UpToDate”数据库中此前未提及40种药物的风险。服用这些药物的患者性别分布相似，大多为45 - 64岁，体重较重（中位数88千克；P < 0.0001）。发病的中位时间为199天（四分位间距27 - 731.5天）。泊那替尼（16.48%）、替加环素（14.12%）和丙戊酸（13.41%）的死亡率较高。在101种药物中的50种中确定了与胰腺炎相关的潜在靶点。
开具这101种药物进行治疗的临床医生应保持警惕，以便早期发现胰腺炎。
